Inventor · disambiguated record
Marion Lanier
Also filed as: LANIER MARION · LANIER MARION C
19 granted patents·14 pending applications·28 citations·filing 2001–2024
91Inventor score
Files withESCIENT PHARMACEUTICALS INC17NEUROCRINE BIOSCIENCES INC3TAKEDA PHARMACEUTICALS CO3MERCOLA MARK2TAKEDA PHARMACEUTICAL2
Top patents by PatentIndex Score
33 records- 0194US11919864B2Modulators of Mas-related G-protein receptor X2 and related products and methodsESCIENT PHARMACEUTICALS INC·Filed 2021·Granted Mar 5, 2024·3 cites·52 claims
- 0294US11667636B2Modulators of Mas-related G-protein receptor X2 and related products and methodsESCIENT PHARMACEUTICALS INC·Filed 2021·Granted Jun 6, 2023·3 cites·32 claims
- 0389US11952346B2Modulators of mas-related G-protein receptor X2 and related products and methodsESCIENT PHARMACEUTICALS INC·Filed 2021·Granted Apr 9, 2024·1 cites·11 claims
- 0488US11970452B2Modulators of mas-related G-protein receptor X2 and related products and methodsESCIENT PHARMACEUTICALS INC·Filed 2021·Granted Apr 30, 2024·1 cites·4 claims
- 0586US9040522B26-(5-hydroxy-1H-pyrazol-1-yl)nicotinamide inhibitors of PHDTAKEDA PHARMACEUTICAL·Filed 2014·Granted May 26, 2015·7 cites·10 claims
- 0685US12129243B2Modulators of Mas-related G-protein receptor X2 and related products and methodsESCIENT PHARMACEUTICALS INC·Filed 2023·Granted Oct 29, 2024·0 cites·11 claims
- 0784US12129244B2Modulators of Mas-related G-protein receptor X2 and related products and methodsESCIENT PHARMACEUTICALS INC·Filed 2023·Granted Oct 29, 2024·0 cites·36 claims
- 0884US2025026735A1Modulators of mas-related g-protein receptor x2 and related products and methodsESCIENT PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 0982US9345713B26-(5-hydroxy-1H-pyrazol-1-yl)nicotinamide inhibitors of PHDTAKEDA PHARMACEUTICAL·Filed 2015·Granted May 24, 2016·3 cites·10 claims
- 1081US12384748B2Modulators of mas-related g-protein receptor X2 and related products and methodsESCIENT PHARMACEUTICALS INC·Filed 2024·Granted Aug 12, 2025·0 cites·10 claims
- 1181US2025289815A1Modulators of mas-related g-protein receptor x2 and related products and methodsESCIENT PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1280US2024059667A1Modulators of mas-related g-protein receptor x2 and related products and methodsESCIENT PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1379US9708296B26-(5-hydroxy-1H-pyrazol-1-yl)nicotinamide inhibitors of PHDTAKEDA PHARMACEUTICALS CO·Filed 2016·Granted Jul 18, 2017·2 cites·8 claims
- 1476US12275707B2Modulators of mas-related g-protein receptor X2 and related products and methodsESCIENT PHARMACEUTICALS INC·Filed 2023·Granted Apr 15, 2025·0 cites·42 claims
- 1576US12240845B2Modulators of mas-related G-protein receptor X2 and related products and methodsESCIENT PHARMACEUTICALS INC·Filed 2023·Granted Mar 4, 2025·0 cites·41 claims
- 1675US7879862B2Pyrazolo[1,5-alpha]pyrimidinyl derivatives useful as corticotropin-releasing factor (CRF) receptor antagonistsSMITHKLINE BEECHAM CORK LTD·Filed 2005·Granted Feb 1, 2011·2 cites·20 claims
- 1774US2024239749A1Modulators of mas-related g-protein receptor x2 and related products and methodsESCIENT PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1872US6747034B2CRF receptor antagonists and methods relating theretoNEUROCRINE BIOSCIENCES INC·Filed 2001·Granted Jun 8, 2004·5 cites·31 claims
- 1967US2025170141A1Mrgprx2 modulators and related methods of treatmentESCIENT PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2067US2024307394A1Modulators of mas-related g-protein receptor d and related products and methodsESCIENT PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2165US7652035B2CRF receptor antagonists and methods relating theretoNEUROCRINE BIOSCIENCE INC·Filed 2005·Granted Jan 26, 2010·1 cites·35 claims
- 2265US2024246980A1Modulators of mas-related g-protein receptor d and related products and methodsESCIENT PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2362US9944626B26-(5-hydroxy-1H-pyrazol-1-YL)nicotinamide inhibitors of PHDTAKEDA PHARMACEUTICALS CO·Filed 2017·Granted Apr 17, 2018·0 cites·7 claims
- 2460US10407409B26-(5-hydroxy-1H-pyrazol-1-yl)nicotinamide inhibitors of PHDTAKEDA PHARMACEUTICALS CO·Filed 2018·Granted Sep 10, 2019·0 cites·2 claims
- 2556US2024254089A1Modulators of mas-related g-protein receptor x4 and related products and methodsESCIENT PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 2652US2004266799A1CRF receptor antagonists and methods relating theretoNEUROCRINE BIOSCIENCES INC·Filed 2004·Application pending·0 cites
- 2745US2010234341A1Substituted pyrimidines as adenosine receptor antagonistsLANIER MARION·Filed 2007·Application pending·0 cites
- 2840US2004053933A1Ligands of melanocortin receptors and compositions and methods related theretoNEUROCRINE BIOSCIENCES INC·Filed 2003·Application pending·0 cites
- 2940US2008275064A1Substituted Pyrimidines as Adenosine Receptor AntagonistsSLEE DEBORAH·Filed 2006·Application pending·0 cites
- 3038US2020277262A1N-(cyano-substituted benzyl or pyridinylmethyl)-3-hydroxypicolinamide derivativesJONES BENJAMIN·Filed 2018·Application pending·0 cites
- 3137US9233926B2Compounds for stem cell differentiationMERCOLA MARK·Filed 2012·Granted Jan 12, 2016·0 cites·12 claims
- 3236US9023340B2Wnt inhibitors for human stem cell differentiationCASHMAN JOHN·Filed 2012·Granted May 5, 2015·0 cites·5 claims
- 3332US2011281356A1Compounds for stem cell differentiationMERCOLA MARK·Filed 2011·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Marion Lanier files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →